The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45+ platelet count and neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45+ platelet count (odds ratio [OR] = 4.51, 95% confidence interval [CI]: 1.50-13.50, P = .007) and neutrophil to lymphocyte ratio (OR = 3.09, 95% CI: 1.05-9.10, P = .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45+ platelet count and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM. Two novel biomarkers of restenosis, CD45+ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict in-stent restenosis after DES implantation in patients with CAD and type 2 DM.

1st Department of Internal Medicine Faculty of Medicine Comenius University Bratislava Slovakia

2nd Department of Surgery Faculty of Medicine Masaryk University and St Anne's University Hospital Brno Czech Republic

Department of Cardiology East Slovak Institute of Cardiovascular Diseases Kosice Slovakia

Department of Internal Medicine Brothers of Mercy Hospital Brno Czech Republic

Faculty of Medicne University of Oviedo Central University Hospital of Asturias Oviedo Spain

Institute of Biomedical Problems of Russian Academy of Sciences Moscow Russian Federation

Russian Cardiology Research and Production Complex Moscow Russian Federation

Zobrazit více v PubMed

Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation. 2005;111(17):2257–2273. PubMed

Wessely R, Kastrati A, Schomig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005;143(5):392–394. PubMed

Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106(21):2649–2651. PubMed

Park DW, Hong MK, Mintz GS, et al. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late “catch-up” phenomenon from ASPECT study. J Am Coll Cardiol. 2006;48(12):2432–2249. PubMed

Claessen BE, Stone GW, Mehran R, et al. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. J Thromb Thrombolysis. 2012;34(2):165–179. PubMed

Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56(22):1783–1793. PubMed

Gabbasov ZA, Kozlov SG, Imaeva AE, et al. In-stent restenosis after revascularization of myocardium with drug-eluting stents is accompanied by elevated level of blood plasma eosinophil cationic protein. Can J Physiol Pharmacol. 2011;89(6):413–448. PubMed

Park DW, Lee CW, Yun SC, et al. Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation. Heart. 2007;93(9):1087–1092. PubMed PMC

Dibra A, Ndrepepa G, Mehilli J, et al. Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents. Am J Cardiol. 2005;95(10):1238–1240. PubMed

Kang WC, Ahn TH, Moon CI, et al. Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents. Heart. 2009;95(12):970–975. PubMed

Gaspardone A, Versaci F, Tomai F, et al. C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents. Am J Cardiol. 2006;97(9):1311–1316. PubMed

Cui S, Li K, Ang L, et al. Plasma phospholipids and sphingolipids identify stent restenosis after percutaneous coronary intervention. JACC Cardiovasc Interv. 2017;10(13):1307–1316. PubMed

Fujimoto H, Suzuki T, Aizawa K, et al. Processed B-type natriuretic peptide is a biomarker of postinterventional restenosis in ischemic heart disease. Clin Chem. 2013;59(9):1330–1337. PubMed

Gabbasov Z, Kozlov S, Byazrova S, et al. Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease. Wien Klin Wochenschr. 2016;128(23-24):898–905. PubMed

Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–1379. PubMed

Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Circ Res. 2012;110(2):356–363. PubMed

Osterud B, Bjorklid E. Tissue factor in blood cells and endothelial cells. Front Biosci (Elite Ed). 2012;4:289–299. PubMed

Owens AP, 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res. 2011;108(10):1284–1297. PubMed PMC

Totani L, Evangelista V. Platelet–leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30(12):2357–2361. PubMed PMC

Gabbasov Z, Ivanova O, Kogan-Yasny V, et al. Activated platelet chemiluminescence and presence of CD45+ platelets in patients with acute myocardial infarction. Platelets. 2014;25(6):405–408. PubMed

Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. Predictive value of elevated neutrophil–lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin Chim Acta. 2008;395(1-2):27–31. PubMed

Uthamalingam S, Patvardhan EA, Subramanian S, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol. 2011;107(3):433–438. PubMed

Balli M, Taşolar H, Çetin M, et al. Use of the neutrophil to lymphocyte ratio for prediction of in-stent restenosis in bifurcation lesions. Eur Rev Med Pharmacol Sci. 2015;19(10):1866–1873. PubMed

Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006;97(7):993–996. PubMed

Turak O, Ozcan F, Isleyen A. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110(10):1405–1410. PubMed

Thiele JR, Habersberger J, Braig D, et al. The dissociation of pentameric to monomeric C-reactive protein localises and aggravates inflammation: in vivo proof of a powerful pro-inflammatory mechanism and a new anti-inflammatory strategy. Circulation. 2014;130(1);35–50. PubMed

Li HY, Wang J, Wu YX, et al. Topological localization of monomeric C-reactive protein determines proinflammatory endothelial cell responses. J Biol Chem. 2014;289(20):14283–14290. PubMed PMC

Khreiss T, József L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation. 2004;109(16):2016–2022. PubMed

Habersberger J, Strang F, Scheichl A, et al. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovascular Res. 2012;96(1):64–72. PubMed

Eisenhardt SU, Habersberger J, Murphy A, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105(2):128–137. PubMed